European regulatory strategy for supporting childhood cancer therapy developments

Area of Science:

• Paediatric Oncology Drug Development
• Regulatory Science
• Oncology Therapeutics

Background:

• Advancements in oncology identify new molecular targets, driving the development of innovative medicines.
• Global regulatory requirements, like the US RACE for Children Act, are evolving for paediatric oncology drug pipelines.
• Paediatric oncology faces challenges due to rare, life-threatening diseases and high unmet medical needs.

Purpose of the Study:

• To explain the EU regulatory decision-making strategy for paediatric oncology.
• To foster evidence generation for drug development based on medical needs and scientific robustness.
• To address challenges in completing paediatric oncology development efforts for innovative products.

Main Methods:

• The EU regulatory decision-making strategy for paediatric oncology is described.
• The concept of paediatric investigation plans (PIPs) as living documents is highlighted.
• Stakeholder engagement through platforms like EMA and ACCELERATE is utilized.

Main Results:

• Regulatory bodies acknowledge feasibility challenges in paediatric oncology drug development.
• Prioritization of products and identification of next-generation therapies are crucial.
• Paediatric investigation plans (PIPs) are adaptable based on new evidence and evolving needs.

Conclusions:

• Regulatory strategies aim to ensure timely availability of effective and safe medicines for children.
• Continuous scientific progress necessitates adaptive regulatory approaches for paediatric oncology.
• Collaboration with stakeholders, including patients and clinicians, is vital for successful paediatric investigation plans.